Author

C. H. June

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 5 Organism:human· 5 Research Focus:cell type annotation· 4 Approach:experimental assay· 3 Assay:scRNA-seq· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell-cell communication· 2

Frequent Co-Authors

E. J. Wherry· 2 shared J. A. Fraietta· 2 shared S. A. Grupp· 2 shared S. L. Berger· 2 shared A. C. Huang· 1 shared A. Chew· 1 shared A. R. Greenplate· 1 shared A. Satpathy· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

E. J. Wherry

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors

Z. Xiao, L. Tood, L. Huang, E. Noguera-Ortega, Z. Lu, L. Huang, M. Kopp, Y. Li, N. B. Pattada, W. Zhong, W. Guo, J. Schollor, M. Liousia, C.-A. Assenmacher, C. H. June, , E. Pure

This study shows that targeting FAP+CAFs in desmoplastic pancreatic tumors reduces stromal barriers, enhances T cell infiltration, and improves response to immunotherapy.

bioRxiv · Apr 13, 2023Immunology

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

C. A. Tsuchida, N. Brandes, R. Bueno, M. Trinidad, T. Mazumder, B. Yu, B. Hwang, C. Chang, J. Liu, Y. Sun, C. R. Hopkins, K. R. Parker, Y. Qi, A. Satpathy, E. Stadtmauer, , J. A. Doudna

This study investigates chromosome loss in CRISPR-Cas9-engineered T cells and shows a modified manufacturing process reduces it while preserving editing efficacy.

bioRxiv · Mar 22, 2023Cell Biology

Induction of a CD8 T cell intrinsic DNA damage and repair response is associated with clinical response to PD-1 blockade in uterine cancer.

Y. Muroyama, S. Manne, N. Wellhausen, D. A. Oldridge, A. R. Greenplate, L. Chilukuri, D. Mathew, C. Xu, R. S. Herati, S. L. Berger, A. C. Huang, C. H. June, D. Zamarin, C. F. Friedman, E. J. Wherry

The paper identifies a CD8 T cell intrinsic DNA damage response linked to clinical response to PD-1 blockade in uterine cancer using high-dimensional single-cell analysis.

bioRxiv · Apr 16, 2022 · PreprintImmunology

Decade-long remissions of leukemia sustained by the persistence of activated CD4+ CAR T-cells

J. J. Melenhorst, G. M. Chen, M. Wang, D. . L. Porter, P. Gao, S. Bandyopadhyay, I. Pruteanu-Malinici, C. L. Nobles, S. Maji, N. V. Frey, S. I. Gill, L. Tian, I. Kulikovskaya, M. Gupta, M. M. Davis, , C. H. June

This study tracks long-term persistence of CD4+ CAR T-cells in CLL patients, showing their role in sustained remission and clonal stability over 10 years.

bioRxiv · May 7, 2021 · PreprintImmunology

Single-cell antigen-specific activation landscape of CAR T infusion product identifies determinants of CD19 positive relapse in patients with ALL

Z. Bai, S. Woodhouse, D. Kim, S. Lundh, H. Sun, Y. Deng, Y. Xiao, D. M. Barrett, R. M. Myers, S. A. Grupp, C. H. June, J. J. J. Joseph Melenhorst, P. G. Camara, R. Fan

The paper analyzes single-cell data from CAR T infusion products to identify factors associated with CD19-positive relapse in ALL patients.

bioRxiv · Apr 15, 2021Immunology

Impaired tumor death receptor signaling drives resistance to CAR T cell therapy

N. Singh, O. Shestova, P. Ravikumar, K. Hayer, S. J. Hong, E. J. Orlando, K. T. Mueller, C. R. Good, S. L. Berger, O. Shalem, M. D. Weitzman, S. A. Grupp, C. H. June, S. Gill, M. Ruella

This study identifies impaired death receptor signaling as a driver of resistance to CAR T cell therapy in B-cell leukemia by showing its role in tumor survival and T cell dysfunction.

bioRxiv · May 5, 2019 · PreprintImmunology